Clinical trial

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

NCT02608216

Study summary

ClinicalTrials.gov

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention [18F]FLT Find medicine records · Find other trials using this name

DEVICE · Unmapped registry intervention PET/CT Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record ribociclib Normalized identity: ribociclib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record paclitaxel Normalized identity: paclitaxel View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2015-11-01

PhasePHASE1

Conditions

Breast Neoplasmverified · MONDO: breast neoplasm

Metastatic Breast Cancerunresolved

Rb+ Breast Cancerunresolved

Interventions

[18F]FLTDRUG

PET/CTDEVICE

ribociclibDRUG · verified · RxNorm: ribociclib

paclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

University of Pennsylvanialead sponsor

Mapped research locations

PhiladelphiaPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02608216 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.